Patent: 9,808,421
✉ Email this page to a colleague
Summary for Patent: 9,808,421
Title: | Bioerodible silicon-based devices for delivery of therapeutic agents |
Abstract: | This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases. |
Inventor(s): | Ashton; Paul (Newton, MA), Canham; Leigh T. (Malvern, GB), Barnett; Christian (Pershore, GB) |
Assignee: | PSIVIDA US, INC. (Watertown, MA) |
Application Number: | 15/299,050 |
Patent Claims: | see list of patent claims |
Details for Patent 9,808,421
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2030-11-01 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2030-11-01 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2030-11-01 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 09/23/2014 | ⤷ Try a Trial | 2030-11-01 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 11/23/2015 | ⤷ Try a Trial | 2030-11-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |